1. Home
  2. RDVT vs TBPH Comparison

RDVT vs TBPH Comparison

Compare RDVT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Violet Inc.

RDVT

Red Violet Inc.

HOLD

Current Price

$69.26

Market Cap

793.2M

Sector

Technology

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.96

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDVT
TBPH
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
793.2M
908.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
RDVT
TBPH
Price
$69.26
$16.96
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$62.00
$18.40
AVG Volume (30 Days)
160.0K
815.7K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
82.00
279.13
EPS
0.30
N/A
Revenue
$90,252,000.00
$15,386,000.00
Revenue This Year
$16.31
$8.46
Revenue Next Year
$13.83
N/A
P/E Ratio
$218.40
N/A
Revenue Growth
20.03
N/A
52 Week Low
$33.40
$10.82
52 Week High
$67.68
$21.03

Technical Indicators

Market Signals
Indicator
RDVT
TBPH
Relative Strength Index (RSI) 81.64 54.48
Support Level $50.66 $16.12
Resistance Level N/A $17.21
Average True Range (ATR) 2.66 0.34
MACD 0.94 0.01
Stochastic Oscillator 92.78 48.69

Price Performance

Historical Comparison
RDVT
TBPH

About RDVT Red Violet Inc.

Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: